Abstract
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have